Expression Therapeutics, Inc. is a fully integrated clinical stage gene and cell therapy company developing novel, potentially curative, therapeutics for deadly childhood and adult genetic diseases.
The Company’s scientific breakthrough in transgene bioengineering and protein engineering enable it to optimize the gene therapy for each target indication: bleeding disorders, primary immunodeficiencies, and cancer. Expression’s clinical programs use both lentiviral (LV) vectors and adeno-associated viral (AAV) vectors.
A multi-platform approach, combined with an understanding of target diseases, make the company a drug development platform, not beholden to a specific technology. The Company’s oncology platform is based on proprietary non-signaling chimeric antigen receptor technology that enhances the targeting capability of gamma delta T cells and alleviates concerns of long-term T cell ablation and tonic signaling to develop allogeneic cell therapies for neuroblastoma, T cell leukemia and lymphoma, and acute myeloid leukemia.
Expression also has a state-of-the-art scalable 43,000 square foot manufacturing facility that is able to produce cGMP LV and AAV vectors, cell therapy products, and recombinant proteins to speed up development of the Company’s clinical programs.